Lenalidomide-Glycolic acid is a E3 Ligase Ligand-Linker Conjugate for PROTAC-class FLT3 degrader LWY713.

Lenalidomide-C13-piperazine-Boc is a conjugate of the E3 ligase ligand and the linker, that can be used for synthesis of PROTAC degrader NC-R17.

Lenalidomide-amide-pimelic acid is an E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based CRBN ligand and Linker. Lenalidomide-amide-pimelic acid can be used for synthesis of PROTAC MNK1 degrader-1.

Lenalidomide-5-Br-amide-C2-Br is an E3 ligase ligand-linker conjugate. Lenalidomide-5-Br-amide-C2-Br can be used to synthesize PROTAC DDR1 degrader-1. Palbociclib is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively.

LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively). LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research.

LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to CDK9 inhibitor SNS-032 through a linker, forming an ATTEC that targets the degradation of the CDK9 and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity.

LC3B recruiter 1 (compound 33R) is an LC3B recruiter fragment. LC3B recruiter 1 directly interacts with LC3B with a KD value of 2.87 µM.

LAU-0901, a PAF receptor antagonist, possesses highly neuroprotective activity. LAU-0901 inhibits apoptosis.

LA-CB1 is an Abemaciclib, which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa.

L321-NH-C3-PEG3-C1-NH2 (CRBN ligand L321) is an E3 Ligase Ligand-Linker Conjugate for BRD4 PROTAC L134.

4-Methylphenoxyacetic acid-Oxindole-CF3 is the E3 ligase ligand part of L134.

KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research.

KU13 is an inhibitor of nontuberculous mycobacteria (NTM). The minimum inhibitory concentrations (MIC) of KU13 against Mycobacterium and E. coli are 0.032-8 μg/mL and 2 μg/mL, respectively. KU13 can be used for research in the field of anti-infection .

KK181N1 is a potent inhibitor of karrikin (KAR) receptor KAI2. KK181N1 binds to the catalytic pockets of KAI2 in a non-covalent binding manner. KK181N1 selectively depress the KAR-induced phenotypes in Arabidopsis.

KF-52 is a phosphofructokinase-1 (PFK1) inhibitor, with an IC50 of 2.1 μM. KF-52 significantly increases the OCR/ECAR (OCR: oxygen consumption rate; ECAR: extracellular acidification rate) ratio.

Ketoprofen (RP-19583) sodium is a non-steroidal anti-inflammatory agent. Ketoprofen sodium can inhibit the activity of Cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). Ketoprofen is potential in the research of inflammation, immunology, and metabolic disease such as obesity.

KCC2 potentiators-1 (Compound 2) is a Potassium chloride cotransporter-2 (KCC2) potentiator. KCC2 potentiators-1 is promising for research of neurological disorder.

Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.

Kalafungin is an antibiotic, antimicrobial agent and a β-lactamase inhibitor from marine Streptomyces, with IC50 of 225.37 μM. Kalafungin destroys cell membranes. Kalafungin shows inhibitory activities against a variety of pathogenic fungi, yeasts, protozoa, gram-positive bacteria (such as S. aureus ATCC 33591 and S. aureus ATCC 23591), and, to a lesser extent, gram-negative bacteria.

KAC-50.1 is an α-Synuclein (α-syn) PET ligand, with a KD of 35 nM toward site 2 in recombinant α-syn fibrils.

JNJ19567470 (R317573) is a selective, non-peptidergic CRF type 1 receptor (CRF1) antagonist. JNJ19567470 blocks NaLac-induced panic-like behaviour and cardiovascular responses. JNJ19567470 decreases regional glucose utilization in the amygdala, and attenuates anxiety responses.

iZMYND8-34 is a histone reader ZMYND8 inhibitor that inhibits ZMYND8's histone recognition. iZMYND8-34 can be used for the research of neuroendocrine prostate cancer.

Itaconic acid prodrug-1 (Compound P2) is an orally active prodrug of Itaconic acid that efficiently delivers the active ingredient Itaconic acid to skin tissue following oral administration. Itaconic acid prodrug-1 possesses immunomodulatory properties, significantly inhibiting Poly(I:C)/IFNγ-induced inflammatory cytokines in human epidermal keratinocytes. Itaconic acid prodrug-1 can be utilized for the research of alopecia areata and other inflammatory skin diseases.

iso-WAY-260022 (Compound 13R) is an orally active, brain-penetrant and selective norepinephrine transporter (hNET) inhibitor with an IC50 value of 140 nM. iso-WAY-260022 also shows inhibitory effects on human serotonin (hSERT) and dopamine transporters (hDAT). iso-WAY-260022 inhibits norepinephrine reuptake and increases hypothalamic norepinephrine levels to regulate thermoregulatory center function. iso-WAY-260022 is promising for research of vasomotor symptoms, such as menopausal hot flushes, night sweats.

Indomethacin N-octyl amide (Compound 2) is a potent and selective COX-2 inhibitor with an IC50 of 40 nM. Indomethacin N-octyl amide shows >1000-fold selectivity against COX-1 (IC50 of 66 µM).

Ifebemtinib (BI-853520) hydrochloride is an orally active and potent focal adhesion kinase (FAK) inhibitor (IC50 = 1 nM for recombinant FAK). Ifebemtinib hydrochloride exhibits antiproliferative activity against cancer cells.

ICD inducer-1 (Compound Re1) is an effective immunogenic cell death (ICD) inducer that can target the endoplasmic reticulum (ER) and block ER-phagy at the late stages. ICD inducer-1 is promising for research of cancers.

Hydroxytyrosol 1-O-glucoside (Dopaol glucoside) is a glycoside with antioxidant activity. Hydroxytyrosol 1-O-glucoside is also an epoxide hydrolase 2 inhibitor.

HW161023 (compound 5) is an orally active AP2-associated protein kinase 1 (AAK1) inhibitor with IC50 values of 5.4 nM and 11.9 μM aganist of AAK1and hERG, respectively. HW161023 inhibits the pain in chronic constriction injury of the sciatic nerve rat model.

HUP-55 is a prolyl endopeptidase inhibitor (IC50 = 5 nM). HUP-55 reduces the dimerization of α-synuclein in Neuro2a cells and induces autophagy (Autophagy) in HEK293 cells. It also decreases the increase in reactive oxygen species (ROS) production induced by hydrogen peroxide in SH-SY5Y cells at a concentration of 10 μM. In a mouse Parkinson’s disease model, HUP-55 (10 mg/kg) improves motor function (reduces the use frequency of the impaired paw) and decreases the levels of harmful oligomers of α-synuclein in the striatum caused by overexpression of α-synuclein.